BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...Preclin Celyad S.A. (NASDAQ:CYAD; Euronext:CYAD) CYAD-101 Allogenic CAR T cells NKG2D Preclin Courier Therapeutics Inc. CT101-IL2...
...have disclosed programs designed to stimulate NK cells in vivo . Courier’s fusion protein CT101-IL2...
BioCentury | Jun 29, 2017
Product R&D

Drop the MIC

...in vitro that MICA and MICB down-regulate the chimeric receptor. Courier Therapeutics Inc. is developing CT101-IL2...
BioCentury | Oct 27, 2016
Targets & Mechanisms

Cancer’s Phoenix

...form of IL-2 are in clinical development, and three others are in preclinical development, including CT101-IL2...
...IL-15 Leukemia Preclinical Pivotal BioSciences Inc. PB101 Low-toxicity analog of IL-2 Cancer Preclinical Courier Therapeutics CT101-IL2...
...immunogenicity. He said the company is planning GMP production of the optimized fusion protein, designated CT101-IL2...
Items per page:
1 - 3 of 3